Nirsevimab

Status:

Red

Decision Date:

January 2023

Comments

RED: Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. 

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again